Table of Contents Author Guidelines Submit a Manuscript
Tuberculosis Research and Treatment
Volume 2013, Article ID 108401, 6 pages
http://dx.doi.org/10.1155/2013/108401
Research Article

Evaluation of MGIT 960 System for the Second-Line Drugs Susceptibility Testing of Mycobacterium tuberculosis

1Korean Institute of Tuberculosis, 168-5, Osong sangmyung 4 ro, Osong-eup, Cheongwon-gun, Chungbuk 363-954, Republic of Korea
2Novartis Korea LTD, CD&MA, Namdaemunro 5-ga, Joon-gu 100-753, Republic of Korea
3Centers for Infectious Diseases, National Institute of Health, Korea Centers for Disease Control and Prevention, 187 Osong sangmyung 2 ro, Osong-eup, Cheongwon-gun, Chungbuk 363-951, Republic of Korea

Received 24 December 2012; Revised 7 March 2013; Accepted 11 March 2013

Academic Editor: Alexander S. Apt

Copyright © 2013 Hyejin Kim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. A. Aziz, A. Wright, A. Laszlo et al., “Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis,” Lancet, vol. 368, no. 9553, pp. 2142–2154, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Banerjee, G. F. Schecter, J. Flood, and T. C. Porco, “Extensively drug-resistant tuberculosis: new strains, new challenges,” Expert Review of Anti-Infective Therapy, vol. 6, no. 5, pp. 713–724, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. N. R. Gandhi, A. Moll, A. W. Sturm et al., “Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa,” Lancet, vol. 368, no. 9547, pp. 1575–1580, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. M. C. Raviglione and I. M. Smith, “XDR tuberculosis—implications for Global Public Health,” New England Journal of Medicine, vol. 356, no. 7, pp. 656–659, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. N. S. Shah, A. Wright, G. H. Bai et al., “Worldwide emergence of extensively drug-resistant tuberculosis,” Emerging Infectious Diseases, vol. 13, no. 3, pp. 380–387, 2007. View at Google Scholar
  6. A. Martin, J. C. Palomino, and F. Portaels, “Rapid detection of ofloxacin resistance in Mycobacterium tuberculosis by two low-cost colorimetric methods: resazurin and nitrate reductase assays,” Journal of Clinical Microbiology, vol. 43, no. 4, pp. 1612–1616, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. N. Morcillo, B. Di Giulio, B. Testani, M. Pontino, C. Chirico, and A. Dolmann, “A microplate indicator-based method for determining the susceptibility of multidrug-resistant Mycobacterium tuberculosis to antimicrobial agents,” International Journal of Tuberculosis and Lung Disease, vol. 8, no. 2, pp. 253–259, 2004. View at Google Scholar · View at Scopus
  8. T. Prammananan, W. Arjratanakool, A. Chaiprasert et al., “Second-line drug susceptibilities of Thai multidrug-resistant Mycobacterium tuberculosis isolates,” International Journal of Tuberculosis and Lung Disease, vol. 9, no. 2, pp. 216–219, 2005. View at Google Scholar · View at Scopus
  9. P. Bemer, T. Bodmer, J. Munzinger, M. Perrin, V. Vincent, and H. Drugeon, “Multicenter evaluation of the MB/BACT system for susceptibility Testing of Mycobacterium tuberculosis,” Journal of Clinical Microbiology, vol. 42, no. 3, pp. 1030–1034, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Heifets, T. Linder, T. Sanchez, D. Spencer, and J. Brennan, “Two liquid medium systems, mycobacteria growth indicator tube and MB redox tube, for Mycobacterium tuberculosis isolation from sputum specimens,” Journal of Clinical Microbiology, vol. 38, no. 3, pp. 1227–1230, 2000. View at Google Scholar · View at Scopus
  11. I. Bastian, L. Rigouts, J. C. Palomino, and F. Portaels, “Kanamycin susceptibility testing of Mycobacterium tuberculosis using Mycobacterium growth indicator tube and a colorimetric method,” Antimicrobial Agents and Chemotherapy, vol. 45, no. 6, pp. 1934–1936, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Krüüner, M. D. Yates, and F. A. Drobniewski, “Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis,” Journal of Clinical Microbiology, vol. 44, no. 3, pp. 811–818, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Palaci, S. Y. M. Ueki, D. N. Sato, M. Alice da Silva Telles, M. Curcio, and E. A. M. Silva, “Evaluation of mycobacteria growth indicator tube for recovery and drug susceptibility testing of Mycobacterium tuberculosis isolates from respiratory specimens,” Journal of Clinical Microbiology, vol. 34, no. 3, pp. 762–764, 1996. View at Google Scholar · View at Scopus
  14. S. Rüsch-Gerdes, G. E. Pfyffer, M. Casal, M. Chadwick, and S. Siddiqi, “Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials,” Journal of Clinical Microbiology, vol. 44, no. 3, pp. 688–692, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Sharma, L. Thibert, P. Chedore et al., “Canadian multicenter laboratory study for standardized second-line antimicrobial susceptibility testing of Mycobacterium tuberculosis,” Journal of Clinical Microbiology, vol. 49, no. 12, pp. 4112–4116, 2011. View at Google Scholar
  16. World Health Organization, “Policy guidance on drug-susceptibility testing (DST) of 2nd antituberculosis drug,” WHO/HTM/TB/2008.392. Geneva, Switzerland, 2008.
  17. K. M. Kam, A. Sloutsky, C. W. Yip et al., “Determination of critical concentrations of second-line anti-tuberculosis drugs with clinical and microbiological relevance,” International Journal of Tuberculosis and Lung Disease, vol. 14, no. 3, pp. 282–288, 2010. View at Google Scholar · View at Scopus
  18. G. Canetti, W. Fox, A. Khomenko et al., “Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes,” Bulletin of the World Health Organization, vol. 41, no. 1, pp. 21–43, 1969. View at Google Scholar · View at Scopus
  19. C. Rodrigues, J. Jani, S. Shenai, P. Thakkar, S. Siddiqi, and A. Mehta, “Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 System,” International Journal of Tuberculosis and Lung Disease, vol. 12, no. 12, pp. 1449–1455, 2008. View at Google Scholar · View at Scopus
  20. J. Van Ingen, S. Simons, R. De Zwaan et al., “Comparative study on genotypic and phenotypic second-line drug resistance testing of Mycobacterium tuberculosis complex isolates,” Journal of Clinical Microbiology, vol. 48, no. 8, pp. 2749–2753, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Piersimoni, C. Lacchini, V. Penati et al., “Validation of the agar proportion and 2 liquid systems for testing the susceptibility of Mycobacterium tuberculosis to moxifloxacin,” Diagnostic Microbiology and Infectious Disease, vol. 57, no. 3, pp. 283–287, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Y. G. Lin, E. Desmond, D. Bonato, W. Gross, and S. Siddiqi, “Multicenter evaluation of Bactec MGIT 960 system for second-line drug susceptibility testing of Mycobacterium tuberculosis complex,” Journal of Clinical Microbiology, vol. 47, no. 11, pp. 3630–3634, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. C. A. Sanders, R. R. Nieda, and E. P. Desmond, “Validation of the use of middlebrook 7H10 agar, BACTEC MGIT 960, and BACTEC 460 12B media for testing the susceptibility of Mycobacterium tuberculosis to levofloxacin,” Journal of Clinical Microbiology, vol. 42, no. 11, pp. 5225–5228, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. F. Giannoni, E. Iona, F. Sementilli et al., “Evaluation of a new line probe assay for rapid identification of gyrA mutations in Mycobacterium tuberculosis,” Antimicrobial Agents and Chemotherapy, vol. 49, no. 7, pp. 2928–2933, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. T. S. Huang, S. S. J. Lee, H. Z. Tu et al., “Use of MGIT 960 for rapid quantitative measurement of the susceptibility of Mycobacterium tuberculosis complex to ciprofloxacin and ethionamide,” Journal of Antimicrobial Chemotherapy, vol. 53, no. 4, pp. 600–603, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Feuerriegel, H. S. Cox, N. Zarkua et al., “Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 8, pp. 3353–3356, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Springer, K. Lucke, R. Calligaris-Maibach, C. Ritter, and E. C. Böttger, “Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 and EpiCenter instrumentation,” Journal of Clinical Microbiology, vol. 47, no. 6, pp. 1773–1780, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. M. J. Ruiz-Serrano, L. Alcala, L. Martinez et al., “In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs,” Antimicrobial Agents and Chemotherapy, vol. 44, no. 9, pp. 2567–2568, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. D. A. Mitchison, “Drug resistance in tuberculosis,” European Respiratory Journal, vol. 25, no. 2, pp. 376–379, 2005. View at Google Scholar